|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There is compelling evidence to indicate an important role for increased local renin-angiotensin system activity in the pathogenesis of cardiac hypertrophy and heart failure.
|
20429690 |
2010 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
CTD_human |
Levosimendan improves cardiac function and survival in rats with angiotensin II-induced hypertensive heart failure.
|
20811386 |
2010 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A candidate gene approach has shown that common genetic variants of the renin-angiotensin-adrenergic pathway can also influence heart failure and may be associated with different outcomes.
|
20814312 |
2011 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, we describe the implication of the renin angiotensin aldosteron system in immunity and heart failure.
|
21503626 |
2011 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Early studies used a candidate gene approach focused mainly on factors within adrenergic and renin-angiotensin pathways that affect heart failure progression and are targeted by standard pharmacotherapeutics.
|
21566223 |
2011 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Additionally, a gene polymorphism of the renin-angiotensin system in development of heart failure was identified as a modifier gene.
|
23907713 |
2014 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of the renin-angiotensin system (RAS) plays a critical role in the pathophysiology of myocardial infarction (MI) and the development of heart failure.
|
24134599 |
2013 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Studies in the 1980s and 1990s demonstrated that inhibition of the renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors improved symptoms and mortality in HF resulting from systolic dysfunction, thus providing a framework to consider the use of β-blockers for HF therapy, contrary to the prevailing wisdom of the time.
|
24286577 |
2014 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism.
|
25036270 |
2015 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therapeutics that antagonize selected neurohormonal pathways, specifically the renin-angiotensin-aldosterone and sympathetic nervous systems, have significantly improved patient outcomes in HF.
|
27058529 |
2016 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Renal sympathetic denervation caused a significant reduction in the levels of noradrenaline (166.62±6.84 vs. 183.48±13.66 pg/ml, P<0.05), plasma renin activity (1.93±0.12 vs. 2.10±0.13 ng/mlh, P<0.05) and B-type natriuretic peptide (71.14±3.86 vs. 83.15±5.73 pg/ml, P<0.05) at eight weeks after RSD in the HF+RSD group.
|
27555054 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Indeed, agents that target the renin-angiotensin-aldosterone system (RAAS) have transformed the way in which we manage heart failure.
|
27671772 |
2017 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Resuming renin-angiotensin blockade at discharge home was associated with a decreased risk of heart failure within 30 days of surgery (0.3% vs 11.8% of cases) and stage IV/V chronic kidney disease at last followup (2.6% vs 25.5%, each p <0.001).
|
27746281 |
2017 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Consensus guidelines recommend the use of mineralocorticoid receptor antagonists (MRAs) for selected patients with symptomatic heart failure and reduced ejection fraction (HFrEF) to reduce morbidity and mortality; however, the use of MRAs in combination with other inhibitors of the renin-angiotensin-aldosterone system increases the risk of hyperkalemia.
|
27842179 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors (ACEi) and mineralocorticoid receptor (MR) antagonists are FDA-approved drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) and are used to treat heart failure.
|
27881412 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several endogenous vasoactive peptides act as adaptive mechanisms, and their augmentation could help to broaden the benefits of renin-angiotensin system inhibitors for patients with heart failure.
|
27919443 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials.
|
28104622 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The renin-angiotensin (RAS) pathway has an important role in the etiology of heart failure and given the importance of RAS as a therapeutic target in various cardiomyopathies, genetic polymorphisms in the RAS genes may modulate the risk and severity of disease in cardiomyopathy patients.
|
28120210 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recurrent hyperkalemia frequently limits use of renin-angiotensin-aldosterone system inhibitors (RAASi) in chronic kidney disease (CKD) patients with hypertension, diabetes, and/or heart failure.
|
28129247 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Stimulation of the renin-angiotensin-aldosterone system (RAAS) and β-adrenergic receptors plays an important role in adult heart failure (HF).
|
28130338 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Blockade of the angiotensin-renin system, with angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs), has been shown to improve cardiac outcomes following myocardial infarction and delay progression of heart failure.
|
28166592 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
We hypothesized that Waon therapy would improve neurohumoral factors, such as natriuretic peptides (NP) and the renin-angiotensin-aldosterone system (RAAS) in HF.Methods and Results:Plasma samples were collected from patients enrolled in the WAON-CHF Study (Waon therapy (n=77) or control (n=73)) before and after the treatment.
|
28202884 |
2017 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The renin-angiotensin system (RAS) is activated in heart failure (HF) and inhibition of RAS is a mainstay therapy for HF.
|
28209222 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Renin-angiotensin aldosterone system (RAAS) inhibitors significantly improve outcome in heart failure (HF) patients with reduced ejection fraction (HFREF), irrespective of the occurrence of worsening renal function (WRF).
|
28209765 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Various basic and clinical studies have established the role of an activated renin-angiotensin (Ang) system and Ang II generation in the progression of HF.
|
28279521 |
2017 |